X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs SUN PHARMA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA SUN PHARMA TORRENT PHARMA/
SUN PHARMA
 
P/E (TTM) x 25.9 15.3 168.8% View Chart
P/BV x 6.3 3.6 175.8% View Chart
Dividend Yield % 3.2 0.2 1,482.9%  

Financials

 TORRENT PHARMA   SUN PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-16
SUN PHARMA
Mar-16
TORRENT PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7201,201 143.2%   
Low Rs1,134706 160.5%   
Sales per share (Unadj.) Rs394.5117.5 335.9%  
Earnings per share (Unadj.) Rs101.819.6 519.4%  
Cash flow per share (Unadj.) Rs116.323.8 488.6%  
Dividends per share (Unadj.) Rs40.001.00 4,000.0%  
Dividend yield (eoy) %2.80.1 2,673.3%  
Book value per share (Unadj.) Rs200.3130.5 153.5%  
Shares outstanding (eoy) m169.222,406.60 7.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.68.1 44.5%   
Avg P/E ratio x14.048.7 28.8%  
P/CF ratio (eoy) x12.340.1 30.6%  
Price / Book Value ratio x7.17.3 97.5%  
Dividend payout %39.35.1 770.1%   
Avg Mkt Cap Rs m241,4352,294,813 10.5%   
No. of employees `00010.914.7 73.9%   
Total wages/salary Rs m8,55947,971 17.8%   
Avg. sales/employee Rs Th6,129.619,169.8 32.0%   
Avg. wages/employee Rs Th785.83,253.0 24.2%   
Avg. net profit/employee Rs Th1,581.33,197.9 49.4%   
INCOME DATA
Net Sales Rs m66,764282,697 23.6%  
Other income Rs m2,1566,170 35.0%   
Total revenues Rs m68,920288,867 23.9%   
Gross profit Rs m27,20483,239 32.7%  
Depreciation Rs m2,46110,135 24.3%   
Interest Rs m1,8594,769 39.0%   
Profit before tax Rs m25,04174,505 33.6%   
Minority Interest Rs m0-11,126 0.0%   
Prior Period Items Rs m0-19 0.0%   
Extraordinary Inc (Exp) Rs m-1,403-6,852 20.5%   
Tax Rs m6,4149,349 68.6%   
Profit after tax Rs m17,22447,159 36.5%  
Gross profit margin %40.729.4 138.4%  
Effective tax rate %25.612.5 204.1%   
Net profit margin %25.816.7 154.6%  
BALANCE SHEET DATA
Current assets Rs m46,622308,646 15.1%   
Current liabilities Rs m32,843132,477 24.8%   
Net working cap to sales %20.662.3 33.1%  
Current ratio x1.42.3 60.9%  
Inventory Days Days7483 89.5%  
Debtors Days Days7988 90.0%  
Net fixed assets Rs m39,029133,606 29.2%   
Share capital Rs m8462,407 35.2%   
"Free" reserves Rs m31,400266,909 11.8%   
Net worth Rs m33,890314,042 10.8%   
Long term debt Rs m18,63731,167 59.8%   
Total assets Rs m90,136542,196 16.6%  
Interest coverage x14.516.6 87.1%   
Debt to equity ratio x0.50.1 554.1%  
Sales to assets ratio x0.70.5 142.1%   
Return on assets %21.29.6 221.1%  
Return on equity %50.815.0 338.4%  
Return on capital %48.517.8 273.5%  
Exports to sales %43.314.0 309.6%   
Imports to sales %6.93.1 218.5%   
Exports (fob) Rs m28,93439,572 73.1%   
Imports (cif) Rs m4,5848,882 51.6%   
Fx inflow Rs m29,18542,171 69.2%   
Fx outflow Rs m6,02121,583 27.9%   
Net fx Rs m23,16520,588 112.5%   
CASH FLOW
From Operations Rs m27,13267,694 40.1%  
From Investments Rs m-7,014-44,549 15.7%  
From Financial Activity Rs m-14,352-19,243 74.6%  
Net Cashflow Rs m5,7673,902 147.8%  

Share Holding

Indian Promoters % 71.5 63.7 112.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 5.1 136.8%  
FIIs % 12.6 23.0 54.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 8.3 106.0%  
Shareholders   26,511 133,026 19.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   ALEMBIC LTD  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SHASUN PHARMA  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS